Announcements2010 Announcements Xenome names Michael Aldridge as Executive Director - 25 May 2010
Biopharmaceutical company Xenome Limited (“Xenome”) today announced
the appointment of Michael Aldridge as Executive Director.
Xenome Completes A$10M Convertible Note Financing: Ongoing Support from Existing Venture Capital Investors - 22 April 2010
Biopharmaceutical company Xenome Limited (“Xenome”) today announced it has completed a convertible note financing for A$10 million from funds associated with Queensland BioCapital Fund (QBF) and GBS Venture Partners (GBS). Both QBF and GBS are existing investors in Xenome.
Xenome Licenses Peptides from xdiscover Library to MedImmune - 23 March 2010
Xenome Limited (“Xenome”) today announced that MedImmune LLC (‘MedImmune”), the biologics unit of AstraZeneca, has exercised its option to obtain exclusive licenses to four peptides from Xenome’s xdiscover™ venom peptide library against an undisclosed target involved in a key pain pathway.
Issuance of Xen2174 Patent in Japan - 4 March 2010
Xenome Limited (“Xenome”) today announced that the Japanese Patent Office has issued patent number 4447783, entitled "Novel Peptides".
2009 Announcements Dr Julie Cherrington Joins Xenome Board - 11 August 2009
Xenome Limited (“Xenome”) today announced that Dr Julie Cherrington has joined the Xenome Board as an independent, Non-Executive Director. Xenome and Axxam initiate discovery partnership focused on novel peptides against GPCR targets - 5 August 2009
Xenome Limited (“Xenome”) today announced it has executed a research collaboration agreement with AxxamSpA (“Axxam”), a leading biotechnology research organization offering early-stage discovery research services for the life science industry. Addition to US patent portfolio for Xen2174 - 23 April 2009
Xenome Limited (“Xenome”) today announced the issuance of US patent 7,507,717 entitled “Type II chi-conotoxin peptides (noradrenaline transporter inhibitors)”.
Xenome Grants MedImmune License to xdiscover™ Venom Peptide Library - 8 January 2009
Xenome Limited (“Xenome”) today announced it has executed a research licence agreement with MedImmune LLC (‘MedImmune”), a wholly owned subsidiary of AstraZeneca.
2008 Announcements
2007 Announcements
2006 Announcements
2005 Announcements
2004 Announcements
2003 Announcements
2002 Announcements
2001 Announcements
2000 Announcements
1999 Announcements
News2010 News The poisonous snail and a drug to treat chronic pain - Times Online 23 March 2010
Venom extracted from snails on the Great Barrier Reef could be used to treat pain in human beings.
2009 News Ian Nisbet presents at the Inaugural Biotech Showcase 2009, San Francisco - 14 January 2009
Xenome attended and presented at the inaugural Biotech Showcase 2009 recently held in San Francisco. This first time meeting attracted just over 300 registrants and 56 presenting companies from the US as well as from abroad. Click the link to view the PowerPoint presentation given by Ian Nisbet, CEO, Xenome Limited and to view the conference website.
2008 News
|
